Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

Articles

Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

June 25th 2024

Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.

Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

June 25th 2024

Medical experts highlight second-line options for treating patients with DLBCL.

Relapsed/Refractory Follicular Lymphoma: Future Directions in Care

September 22nd 2023

Key opinion leaders Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the evolving treatment landscape of follicular lymphoma and look toward future evolutions in the field.

Patient Scenario 2: A 53-Year-Old Man With Relapsed/Refractory FL

September 22nd 2023

Centering discussion on a second patient scenario of follicular lymphoma, key opinion leaders consider best therapy for patients with early or aggressive relapse.

Relapsed/Refractory Follicular Lymphoma: EZH2- and PIK3-Targeted Therapies

September 15th 2023

A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.

Relapsed/Refractory Follicular Lymphoma Treatment Armamentarium

September 15th 2023

Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.

Follicular Lymphoma: Patient Monitoring and Maintenance Therapy

September 8th 2023

Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.

Role of BTK Inhibitors in Relapsed/Refractory Follicular Lymphoma

September 1st 2023

A brief review of BTK inhibitor therapy and its potential role within the relapsed/refractory follicular lymphoma treatment landscape.

Patient Scenario 1: An 83 -Year-Old With Relapsed/Refractory FL

September 1st 2023

Centering discussion on a patient scenario of relapsed/refractory follicular lymphoma, key opinion leaders consider how they would select best available therapy in this setting.

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

August 7th 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023

July 31st 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

July 31st 2023

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

What is the Role of Bispecifics in Relapsed/Refractory DLBCL?

July 17th 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy

July 17th 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Evolving Treatment Landscape of Relapsed/Refractory Follicular Lymphoma

July 14th 2023

A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.

Recent Treatment Guideline Updates in Follicular Lymphoma

July 14th 2023

Experts Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, reflect on recent updates to the treatment guidelines for patients with follicular lymphoma.

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.